scholarly article | Q13442814 |
P356 | DOI | 10.1038/S41375-018-0364-X |
P698 | PubMed publication ID | 30700841 |
P50 | author | Daniel Romo | Q86809535 |
P2093 | author name string | Rong Chen | |
William G Wierda | |||
Shuxing Zhang | |||
Yuling Chen | |||
William Plunkett | |||
Mingzhao Zhu | |||
Kenneth G Hull | |||
Wesley Skillern | |||
Qun Qin | |||
Omar Robles | |||
Rajan R Chaudhari | |||
P2860 | cites work | eIF4A3 is a novel component of the exon junction complex | Q24305305 |
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia | Q24313505 | ||
Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation | Q24531417 | ||
MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2 | Q24563123 | ||
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol | Q24805832 | ||
Defining the role of mTOR in cancer | Q28235431 | ||
Structure of the exon junction core complex with a trapped DEAD-box ATPase bound to RNA | Q28259974 | ||
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis | Q29547538 | ||
Molecular mechanisms of mTOR-mediated translational control | Q29615529 | ||
Natural products as sources of new drugs over the 30 years from 1981 to 2010 | Q29616640 | ||
Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
Natural products as chemical probes | Q33590047 | ||
Chemo- and site-selective derivatizations of natural products enabling biological studies | Q33699233 | ||
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia | Q33721114 | ||
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. | Q33806087 | ||
Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation | Q34375074 | ||
Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A | Q34520772 | ||
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia | Q34568840 | ||
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells | Q35176904 | ||
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer | Q35216351 | ||
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death | Q35848241 | ||
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
Isolation and identification of eukaryotic initiation factor 4A as a molecular target for the marine natural product Pateamine A. | Q36965257 | ||
Diagnosing and exploiting cancer's addiction to blocks in apoptosis | Q37059647 | ||
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia | Q37187536 | ||
Natural products as probes for new drug target identification | Q37277209 | ||
Translational control in cancer. | Q37717999 | ||
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells | Q37725415 | ||
Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia | Q37771674 | ||
Current and future directions in mammalian target of rapamycin inhibitors development | Q37836904 | ||
Targeting the eIF4A RNA helicase as an anti-neoplastic approach | Q38252428 | ||
Second-generation derivatives of the eukaryotic translation initiation inhibitor pateamine A targeting eIF4A as potential anticancer agents | Q38346557 | ||
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. | Q38776895 | ||
Substrate-dependent targeting of eukaryotic translation initiation factor 4A by pateamine A: negation of domain-linker regulation of activity. | Q39333883 | ||
Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. | Q40366805 | ||
Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine. | Q40801780 | ||
bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells | Q41234110 | ||
Molecular dynamics simulation of the allosteric regulation of eIF4A protein from the open to closed state, induced by ATP and RNA substrates | Q41888376 | ||
Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. | Q43559954 | ||
Evidence for separate binding and scaffolding domains in the immunosuppressive and antitumor marine natural product, pateamine a: design, synthesis, and activity studies leading to a potent simplified derivative | Q45028817 | ||
Discovery and Characterization of a Eukaryotic Initiation Factor 4A-3-Selective Inhibitor That Suppresses Nonsense-Mediated mRNA Decay. | Q48235539 | ||
Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists | Q48581580 | ||
Impact of recovery on fraction unbound using equilibrium dialysis | Q48786172 | ||
The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs. | Q52339079 | ||
Editorial: Strategies for cellular target identification of natural products. | Q53721548 | ||
RNA-Mediated Sequestration of the RNA Helicase eIF4A by Pateamine A Inhibits Translation Initiation | Q62065986 | ||
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery | Q82676939 | ||
Pateamine: a potent cytotoxin from the New Zealand Marine sponge, mycale sp. | Q104987950 | ||
P433 | issue | 7 | |
P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
P1104 | number of pages | 12 | |
P304 | page(s) | 1663-1674 | |
P577 | publication date | 2019-01-30 | |
P1433 | published in | Leukemia | Q6534498 |
P1476 | title | Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia | |
P478 | volume | 33 |
Search more.